1-3 of 3
Andrea Harzstark
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P15: Treatment (TX) of advanced melanoma during the Coronavirus Disease 2019 (COVID-19) pandemic in Kaiser Permanente Northern California (KPNC)

Free
Juraj Kavecansky, Nina Shah, Angeles Price, Frank Hsieh, Alice Kengla, Belinda Ark, Jahan Tavakoli, Christine Kaiser, Mingqing Li, Sejal Jhatakia, Mala Reddy, Dazhi Cen, Philip Sardar, Stephen Wang, Ashok Pai, Andrea Harzstark, Tatjana Kolevska, Thach-Giao Truong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): P15.
https://doi.org/10.1158/1557-3265.COVID-19-21-P15
Published: 15 March 2021
View articletitled, Abstract P15: Treatment (TX) of advanced melanoma during the Coronavirus Disease 2019 (COVID-19) pandemic in Kaiser Permanente Northern California (KPNC)
Journal Articles

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

Free
Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen-Chuan Ou, Daniel Castellano, Chia-Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Sarah Beall, Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 3012–3022.
https://doi.org/10.1158/1078-0432.CCR-13-3006
Published: 29 May 2014
View articletitled, Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
Open the PDF for Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

Free
Eric Angevin, Jose A. Lopez-Martin, Chia-Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, Daniel Castellano, Jean-Charles Soria, Paramita Sen, Julie Chang, Michael Shi, Andrea Kay, Bernard Escudier
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1257–1268.
https://doi.org/10.1158/1078-0432.CCR-12-2885
Published: 03 March 2013
View articletitled, Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Open the PDF for Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data